Massivemarkets

PCRX

Pacira BioSciences, Inc. Common Stock

Nasdaq · usd

—+0.02 (+0.05%)
As of 7:30:04 PM EST on Nov 16, 2026 · 15-minute delayed

Stock performance

How Pacira BioSciences, Inc. Common Stock (PCRX) stock has performed from one day to one year, with its 52-week range.

-0.01%
-$0.01 over 1D
$36.48$36.48$36.49$36.499:20 AM11:05 AM12:50 PM2:30 PM8:00 PM$36.49
1D
+0.05%
1W
+0.05%
1M
+0.39%
YTD
+40.96%
1Y
+49.94%
52-wk range
$18.80 – $36.67

Key statistics

Today's trading snapshot for PCRX: day range, open, previous close, volume and market cap.

Day range
—
Open
—
Prev close
$36.48
Volume
0
Market cap
$1.46B
Shares out
40.09M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Pacira BioSciences, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

P/E
38.59
P/S
1.96
P/B
2.04
P/FCF
8.62
ROE
5.3%
ROA
3.1%
Debt/Equity
0.41
Div yield
0.00%

As of Nov 16, 2026

8-K filings

Material corporate events Pacira BioSciences, Inc. Common Stock has disclosed to the SEC on Form 8-K.

  • Debt retirementNov 17, 2026

    On November 17, 2026, $96,392.50, which represented all amounts outstanding under the Credit Agreement, was repaid in full, the Credit Agreement and all commitments thereunder were terminated and all liens securing obligations under the Credit Agreement will be released.

  • Material charge or gainNov 12, 2026

    In June 2025, the U.S. District Court for the District of Nevada issued judgment in favor of the Company declaring that RDF was required to repay Pacira $23.1 million in royalties on EXPAREL sales that were previously paid under protest. The District Court also awarded Pacira an additional interest payment of $5.2 million in statutory interest on the royalties paid under protest.

  • Tender offerNov 5, 2026

    On October 30, 2026, Purchaser commenced a tender offer (the "Offer") to purchase all of the issued and outstanding shares of common stock ... of the Company for $36.50 per Share, in cash, net of applicable withholding taxes and without interest.

  • Acquisition agreementOct 8, 2026

    Pursuant to the Merger Agreement, Purchaser will commence a cash tender offer to acquire all of the outstanding shares of common stock of the Company... at an offer price of $36.50 per Share in cash.

  • Divestiture agreementJun 30, 2026

    On June 28, 2026, Pacira BioSciences, Inc. (the "Company") and Pacira CryoTech, Inc., the Company's wholly owned subsidiary (the "Subsidiary"), entered into a Stock and Asset Purchase Agreement (the "Purchase Agreement") with Zimmer, Inc. (the "Purchaser"), a subsidiary of Zimmer Biomet Holdings, Inc. ("Zimmer Biomet"). Pursuant to the Purchase Agreement, the Company has agreed to divest to the Purchaser (i) all of the issued and outstanding capital stock of the Subsidiary and (ii) certain assets and liabilities of the Company and certain of its subsidiaries relating to the Company's handheld cryoanalgesia devices and related products, including iovera®° (the "Transaction") for up to $140.0 million, including an upfront payment of $70.0 million.

PCRX short interest

How heavily PCRX is shorted: shares short, days to cover and average daily volume.

Days to cover
3.9
Short interest
3.35M
Avg volume
855.6K

As of · reported to FINRA twice monthly.

PCRX news

The latest news and headlines about Pacira BioSciences, Inc. Common Stock (PCRX).

Frequently asked questions

What is the Pacira BioSciences, Inc. Common Stock (PCRX) stock price today?

Massive provides real-time and historical Pacira BioSciences, Inc. Common Stock (PCRX) quotes via REST API, WebSocket and MCP.

What is Pacira BioSciences, Inc. Common Stock?

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients.

What is the short interest in PCRX?

As of Oct 30, 2026, PCRX has 3.35M shares short and 3.9 days to cover.

What exchange is PCRX listed on?

Pacira BioSciences, Inc. Common Stock (PCRX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

Build with AI

Build an analysis of PCRX with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a PCRX analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.